Why is Balaxi Pharma falling/rising?

As of 17-Sep, Balaxi Pharmaceuticals Ltd is currently priced at 46.20, reflecting a slight increase of 0.15 or 0.33%. The stock has outperformed its sector today by 0.39%, although it remains below its 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has shown a positive return of 1.58%, but it has underperformed over the last month with a decline of 3.16%. The company has strong long-term fundamental strength, evidenced by an average Return on Equity (ROE) of 30.97% and a favorable Price to Book Value of 1.1. However, the stock has faced significant challenges, including a dramatic decline in profits by 49.8% over the past year, and negative quarterly results that have led to a 95.5% drop in profit after tax.
In the broader market context, Balaxi Pharmaceuticals has underperformed against the benchmark, with a year-to-date return of -36.11% compared to the Sensex's 7.13%. This consistent underperformance over the last three years, coupled with a decrease in institutional investor participation by 7.16%, raises concerns about the stock's future prospects. The falling participation from institutional investors, who typically have better resources to analyze company fundamentals, suggests a lack of confidence in the stock's recovery. Overall, while there are some positive indicators, the significant declines in profitability and investor participation contribute to a challenging outlook for Balaxi Pharmaceuticals.